Gentium S.p.A. (NASDAQ: GENT), a biopharmaceutical company, specializes in discovering, researching, developing and manufacturing active ingredients derived from natural sources as potential therapeutic agents. The company focuses on developing relationships with industrial and academic institutions and intends to discover further beneficial effects of its products as well as develop pharmaceuticals with a broader range of treatment indications. For further information, visit the Company’s web site at http://www.gentium.com.
- 17 years ago
QualityStocks
Gentium S.p.A. (NASDAQ: GENT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – AI-Driven Energy Demands Highlight Strategic Value of Platinum Group Metals Ltd.’s (NYSE American: PLG) (TSX: PTM) Waterberg Project
As the rise of AI-generated services places extreme pressure on the global power grid, Platinum Group…
-
QualityStocksNewsBreaks – Spotlight on ONAR Holding Corp.’s (ONAR) Strategic Playbook: AI-Optimized Campaigns
ONAR (OTCQB: ONAR) was featured in a recent article that discussed its strategy amid the AI…
-
QualityStocksNewsBreaks – Why AI Maverick Intel Inc. (BINP) Is ‘One to Watch’
AI Maverick Intel (OTCID: BINP) recently rebranded and adopted a new strategic direction focused on…